Advertisement
Screener

ImageneBio, Inc. (IMA) EBITDA

ImageneBio, Inc. (IMA) EBITDA

  • 2026-06-30: Basis Reported; EBITDA (m); Operating income -$11.78M; Depreciation and amortization (m).
  • 2026-03-31: Basis Reported; EBITDA (m); Operating income -$12.08M; Depreciation and amortization (m).
  • 2025-09-30: Basis Reported; EBITDA (m); Operating income -$26.59M; Depreciation and amortization (m).
  • 2025-06-30: Basis Reported; EBITDA (m); Operating income -$7.36M; Depreciation and amortization (m).

Complete source-backed ebitda history.

Available history
2024-12-31 to 2025-12-31
Data captured

Historical EBITDA

EBITDA 3 month

DateBasisEBITDAOperating incomeDepreciation and amortizationRevenueEBITDA marginCapital spendingOperating cash flowCost of products and servicesResearch and developmentSelling, general and administrationIncome tax expense / benefit
2026-06-30Reported(m)-$11.78M(m)(m)(m)(m)-$9.07M*(m)$6.67M(m)$16.00K
2026-03-31Reported(m)-$12.08M(m)(m)(m)(m)-$14.80M(m)$5.96M(m)$10.00K
2025-09-30Reported(m)-$26.59M(m)$0.00*(m)(m)-$21.50M*(m)$15.56M(m)-$74.00K
2025-06-30Reported(m)-$7.36M(m)$0.00*(m)(m)-$11.90M*(m)$5.65M(m)$15.00K
2025-03-31Reported(m)-$6.00M(m)$800.00K(m)(m)-$7.23M(m)$4.04M(m)$28.00K
2024-09-30Reported(m)-$2.04M(m)$3.50M(m)(m)$12.96M*(m)$3.88M(m)$0.00
2024-06-30Reported(m)-$15.82M(m)(m)(m)(m)-$12.50M*(m)$9.83M(m)$62.00K
2024-03-31Reported(m)-$18.23M(m)(m)(m)(m)-$18.30M(m)$9.64M(m)$27.00K
2023-09-30Reported(m)-$19.50M(m)$1.19M(m)$0.00*-$20.00M*(m)$14.65M(m)(m)
2023-06-30Reported(m)-$18.49M(m)$2.00M(m)$0.00*-$18.14M*(m)$15.17M(m)(m)
2023-03-31Reported(m)-$15.52M(m)$5.31M(m)$152.00K-$19.78M(m)$15.55M(m)(m)
2022-09-30Reported(m)-$17.88M(m)$6.40M(m)$1.13M*-$17.22M*(m)$18.85M(m)(m)
2022-06-30Reported(m)-$20.95M(m)$382.00K(m)$36.00K*-$19.45M*(m)$15.49M(m)(m)
2022-03-31Reported(m)-$16.96M(m)$3.38M(m)$33.00K-$19.78M(m)$14.34M(m)(m)
2021-09-30Reported(m)-$14.52M(m)$3.75M(m)$184.00K*-$17.99M*(m)$13.38M(m)(m)
2021-06-30Reported(m)-$12.69M(m)$3.55M(m)$187.00K*-$15.72M*(m)$11.37M(m)(m)
2021-03-31Reported(m)-$9.72M(m)$3.47M(m)$839.00K-$13.17M(m)$10.02M(m)(m)
2020-09-30Reported(m)-$6.23M(m)$2.83M(m)$0.00*-$7.67M*(m)$7.22M(m)(m)
2020-06-30Reported(m)-$5.06M(m)$3.07M(m)-$1.00K*-$7.71M*(m)$6.33M(m)(m)
2020-03-31Reported(m)-$7.18M(m)$3.23M(m)$117.00K-$9.87M(m)$7.89M(m)(m)

EBITDA 12 month

DateBasisEBITDAOperating incomeDepreciation and amortizationRevenueEBITDA marginCapital spendingOperating cash flowCost of products and servicesResearch and developmentSelling, general and administrationIncome tax expense / benefit
2025-12-31Reported-$48.05M(m)(m)(m)(m)(m)-$47.84M(m)$28.52M(m)-$350.00K
2024-12-31Reported-$35.9M(m)(m)(m)(m)(m)-$21.32M(m)$32.11M(m)$13.00K
2023-12-31Reported(m)-$75.42M(m)$9.16M(m)$414.00K-$79.74M(m)$59.65M(m)-$162.00K
2022-12-31Reported(m)-$70.90M(m)$15.62M(m)$1.43M-$74.11M(m)$64.32M(m)$0.00
2021-12-31Reported(m)-$34.14M(m)$30.98M(m)$1.76M-$60.25M(m)$47.11M(m)$0.00
2020-12-31Reported(m)-$44.52M(m)$9.19M(m)$766.00K-$37.83M(m)$44.85M(m)(m)

Similar stocks

Stock NameCountryMarket CapPE Ratio
Inmune Bio, Inc. (INMB)United States$0.056B-2.48
BioAtla, Inc. (BCAB)United States$0.058B-0.21
EXOZYMES INC. (EXOZ)United States$0.058B
MiNK Therapeutics, Inc. (INKT)United States$0.063B-5.37
Tevogen Inc. (TVGN)United States$0.049B
Instil Bio, Inc. (TIL)United States$0.048B-1.73
Eloxx Pharmaceuticals, Inc. (ELOX)United States$0.065B
LeonaBio, Inc. (LONA)United States$0.047B-0.61
Metagenomi Therapeutics, Inc. (MGX)United States$0.044B-0.48
BioStem Technologies, Inc. (BSEM)United States$0.069B